البحث عن طبيب

Hani M. Babiker, M.D.

طلب موعد

المنشورات

  1. Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14 [Epub ahead of print]
    View PubMed
  2. Barnett RM, Jang A, Lanka S, Fu P, Bucheit LA, Babiker H, Bryce A, Meyer HM, Choi Y, Moore C, Garje R, Gao X, Kim DW, Chang RY, Gulhati P, Ramaker R, Bansal R, Zhang T, Oliver Sartor A, Armstrong AJ, Bilen MA, Barata P. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. Commun Med (Lond). 2024 Dec 2; 4 (1):256 Epub 2024 Dec 02
    View PubMed
  3. Nakka NMR, Rachamala HK, Angom RS, Indla NR, Dutta SK, Wang E, Bhattacharya S, Sesha Sainath AV, Babiker H, Pal K, Mukhopadhyay D. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Mater Today Bio. 2024 Oct; 28:101199 Epub 2024 Aug 10
    View PubMed
  4. Elhariri A, Patel J, Mahadevia H, Albelal D, Ahmed AK, Jones JC, Borad MJ, Babiker H. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. Target Oncol. 2024 Sep; 19 (5):679-689 Epub 2024 Aug 10
    View PubMed
  5. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
  6. Imperial R, Mosalem O, Majeed U, Tran NH, Borad MJ, Babiker H. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Clin Exp Gastroenterol. 2024; 17:121-134 Epub 2024 Apr 18
    View PubMed
  7. Mahadevia H, Uson Junior PLS, Wang J, Borad M, Babiker H. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. Expert Opin Pharmacother. 2024 Jan-Apr; 25 (1):79-90 Epub 2024 Feb 01
    View PubMed
  8. Aslam FN, Loveday TA, Junior PLSU, Truty M, Smoot R, Bekaii-Saab T, Stucky CC, Babiker H, Borad MJ. APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients. Ann Gastroenterol. 2024 Jan-Feb; 37 (1):95-103 Epub 2023 Dec 20
    View PubMed
  9. Anisetti B, Ahmed AK, Coston T, Gardner L, Majeed U, Reynolds J, Babiker H. Delayed brain metastasis in recurrent hepatocellular carcinoma following liver transplantation: a case report highlighting the predictive value of microvascular invasion. Clin J Gastroenterol. 2023 Dec; 16 (6):864-870 Epub 2023 Aug 02
    View PubMed
  10. Babiker HM, Kay MD, Stuehm C, Woodhead G, Kuo PH. A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study). Oncologist. 2023 Nov 2; 28 (11):e1114-e1117
    View PubMed
  11. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
    View PubMed
  12. Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, McWilliams R, Ma WW, Bekaii-Saab TS, Stauffer J, Starr JS. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precis Oncol. 2023 Aug; 7:e2200706
    View PubMed
  13. Elhariri A, Starr JS, Bagaria S, Tran N, Babiker H. A Unicorn Disease: The Large Duct Variant of Invasive Ductal Adenocarcinoma of the Pancreas. Cureus. 2023 Jul; 15 (7):e41430 Epub 2023 July 05
    View PubMed
  14. Uson PLS, Bearss J, Babiker HM, Borad M. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma. Expert Opin Drug Saf. 2023 Jul-Dec; 22 (8):637-641 Epub 2023 June 26
    View PubMed
  15. Wang J, Karime C, Majeed U, Starr JS, Borad MJ, Babiker HM. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Expert Opin Investig Drugs. 2023 May; 32 (5):387-399 Epub 2023 Apr 24
    View PubMed
  16. Anisetti B, Coston TW, Ahmed AK, Mahadevia HJ, Edgar MA, Starr JS, Babiker HM. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing. Cureus. 2023 Apr; 15 (4):e37239 Epub 2023 Apr 07
    View PubMed
  17. Al-Heeti O, Wu EL, Ison MG, Saluja RK, Ramsey G, Matkovic E, Ha K, Hall S, Banach B, Wilson MR, Miller S, Chiu CY, McCabe M, Bari C, Zimler RA, Babiker H, Freeman D, Popovitch J, Annambhotla P, Lehman JA, Fitzpatrick K, Velez JO, Davis EH, Hughes HR, Panella A, Brault A, Staples JE, Gould CV, Tanna S. Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis. Clin Infect Dis. 2023 Feb 8; 76 (3):e1320-e1327
    View PubMed
  18. Uson Junior PLS, Bearss J, Babiker HM, Borad MJ. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials. Expert Opin Investig Drugs. 2023 Jan; 32 (1):69-75 Epub 2023 Jan 30
    View PubMed
  19. Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov I. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res 2022 Dec 1; 28 (23):5079-5087
    View PubMed
  20. Rutenberg MS, Hoppe BS, Starr JS, Awad Z, Thomas M, Morris CG, Johnson P, Henderson RH, Jones JC, Gharia B, Bowers S, Wolfsen HC, Krishnan S, Ko SJ, Babiker HM, Nichols RC Jr. Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes. Int J Part Ther. 2023 Winter; 9 (3):18-29 Epub 2022 Dec 19
    View PubMed
  21. Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opin Pharmacother. 2022 Dec; 23 (18):2079-2089 Epub 2022 Nov 28
    View PubMed
  22. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
  23. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  24. Larson K, Russ A, Arif-Tiwari H, Mahadevan D, Elliott A, Bhattacharyya A, Babiker H. Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks. J Immunother. 2022 May 1; 45 (4):222-226
    View PubMed
  25. Banh C, Valsvik K, Arredondo A, Notbohm K, Elquza E, Babiker H, Kraft A, Boiles AR, Persky D, Ortega A, McBride A. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30 (3):2755-2766 Epub 2021 Nov 26
    View PubMed
  26. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
  27. Babiker H, Schlegel PJ, Hicks LG, Bullock AJ, Burhani N, Mahadevan D, Elquza E, Borad MJ, Benaim E, Peterson C, Heaton C, Ocean AJ. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Invest New Drugs. 2022 Feb; 40(1):81-90. Epub 2021 Aug 21.
    View PubMed
  28. Karime C, Wang J, Woodhead G, Mody K, Hennemeyer CT, Borad MJ, Mahadevan D, Chandana SR, Babiker H. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs. 2022 Jan; 31 (1):1-13 Epub 2021 Dec 28
    View PubMed
  29. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol. 2022; 12:966534. Epub 2022 Sep 15.
    View PubMed
  30. Arvind R, Chandana SR, Borad MJ, Pennington D, Mody K, Babiker H. Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. Crit Rev Oncol Hematol. 2021 Dec; 168:103535 Epub 2021 Nov 19
    View PubMed
  31. Sinniah RS, Shapses MS, Ahmed MU, Babiker H, Chandana SR. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opin Investig Drugs. 2021 Oct; 30 (10):1047-1056 Epub 2021 Oct 12
    View PubMed
  32. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16; 385 (12):1091-1103 Epub 2021 June 23
    View PubMed
  33. Algotar AM, Hsu CH, Chow HH, Dougherty ST, Babiker HM, Marrero DG, Abraham I, Kumar R, Ligibel JA, Courneya KS, Smith TE, Jones PA, Lopez JN, Niemiro G, Ramakumar S, Hoy RD, Mack C, Thomson CA. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2021 Sep; 24 (3):903-909 Epub 2021 Mar 25
    View PubMed
  34. Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos KP, Crittenden M, Formenti S, Giralt J, Garrido P, Soria A, Hervas-Moron A, Mohan KK, Fury M, Lowy I, Mathias M, Feng M, Li J, Stankevich E. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist. 2021 Sep; 26 (9):e1508-e1513 Epub 2021 May 22
    View PubMed
  35. Powles T, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Flechon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, KEYNOTE-361 Investigators. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jul; 22 (7):931-945 Epub 2021 May 26
    View PubMed
  36. Martinez F, Brucks E, Otsuji J, Mehnoor H, Arif-Tiwari H, Babiker HM, Recio-Boiles A. Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary. JCO Precis Oncol. 2021 Jun; 5:981-987 Epub 2021 June 10
    View PubMed
  37. Sipra QUAR, Islam M, Riaz IB, Zhaohui J, Babiker HM, Bekaii-Saab TS, Sonbol MB. Contemporary Management of Pancreatic Cancer from an Internist Perspective. Am J Med. 2021 May; 134 (5):576-586 Epub 2020 Dec 11
    View PubMed
  38. Algotar AM, Kumar R, Babiker HM, Dougherty ST, Hsu CH, Chow HH, Smith TE, Marrero DG, Courneya KS, Abraham I, Ligibel JA, Thomson CA. Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2). Contemp Clin Trials Commun. 2021 Mar; 21:100701 Epub 2021 Jan 13
    View PubMed
  39. Dohogne B, Arif-Tiwari H, Bracamonte E, Babiker HM. Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation. Anticancer Drugs. 2021 Mar 1; 32 (3):337-343
    View PubMed
  40. Zahir H, Kobayashi F, Zamora C, Gajee R, Gordon MS, Babiker HM, Wang Q, Greenberg J, Wagner AJ. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein. J Clin Pharmacol. 2021 Mar; 61(3):298-306. Epub 2020 Sep 12.
    View PubMed
  41. Chaudhry R, Usama SM, Babiker HM. Physiology, Coagulation Pathways StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  42. Altabakhi IW, Babiker HM. Paraneoplastic Limbic Encephalitis StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  43. Recio-Boiles A, Babiker HM. Esophageal Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  44. Musick SR, Smith M, Rouster AS, Babiker HM. Hepatoblastoma StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  45. Myers DJ, Babiker HM. Benign Mesothelioma StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  46. Salen P, Babiker HM. Hemophilia A StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  47. Recio-Boiles A, Hoilat GJ, Smith M, Babiker HM. Hepatobiliary Tract Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  48. Kaseb H, Kuhn J, Babiker HM. Rhabdomyosarcoma StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  49. Pillai AA, Fazal S, Babiker HM. Polycythemia StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  50. Babiker HM, Hoilat GJ, Recio-Boiles A. Mucinous Cystic Pancreatic Neoplasms StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  51. Kaseb H, Babiker HM. Hodgkin Lymphoma StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  52. Recio-Boiles A, Babiker HM. Liver Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  53. Recio-Boiles A, Babiker HM. Gastric Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  54. Kaseb H, Annamaraju P, Babiker HM. Monoclonal Gammopathy Of Undetermined Significance StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  55. Sabih A, Babiker HM. Von Willebrand Disease StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  56. Recio-Boiles A, Kashyap S, Babiker HM. Gallbladder Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  57. Kaseb H, Durer C, Fazal S, Babiker HM. Plasma Cell Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  58. Recio-Boiles A, Kashyap S, Tsoris A, Babiker HM. Rectal Cancer StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  59. Durer C, Babiker HM. Adult T Cell Leukemia StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  60. Paluri R, Babiker HM. Solid and Papillary Epithelial Neoplasm StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  61. Kaseb H, Babiker HM. Eccrine Carcinoma StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  62. Medina Pabon MA, Babiker HM. A Review Of Hereditary Colorectal Cancers StatPearls Treasure Island (FL) StatPearls Publishing 2021 Jan
    View PubMed
  63. Babiker HM, Kashyap S, Mehta SR, Lekkala MR, Cagir B. Anal Cancer Treasure Island (FL): StatPearls Publishing. 2021 Jan.
    View PubMed
  64. Chandana SR, Babiker HM, Mahadevan D. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics. Expert Opin Investig Drugs. 2020 Dec; 29 (12):1413-1429 Epub 2020 Nov 06
    View PubMed
  65. Liau J, Vedantham S, Babiker HM, McGlothin T, Martin DR.. Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging Annals of Pancreatic Cancer. 2020; 3:15.
  66. Iesa MAM, Osman MEM, Hassan MA, Dirar AIA, Abuzeid N, Mancuso JJ, Pandey R, Mohammed AA, Borad MJ, Babiker HM, Konozy EHE. SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New Microbes New Infect. 2020 Nov; 38:100817 Epub 2020 Nov 19
    View PubMed
  67. Recio-Boiles A, Karass M, Galeas JN, Sukrithan V, Gutwein AH, Babiker HM. Implementation of a Low-Cost Quality Improvement Intervention Increases Adherence to Cancer Screening Guidelines and Reduces Healthcare Costs at a University Medical Center. J Cancer Educ. 2020 Oct; 35(5):930-936.
    View PubMed
  68. Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020 Aug; 8(2).
    View PubMed
  69. Sprissler R, Perkins B, Johnstone L, Babiker HM, Chalasani P, Lau B, Hammer M, Mahadevan D. Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations. Cancers (Basel). 2020 Jun 18; 12(6).
    View PubMed
  70. Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020 May; 85 (5):1009-1010
    View PubMed
  71. Larson K, Kannaiyan R, Pandey R, Chen Y, Babiker HM, Mahadevan D. A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes. Cancers (Basel). 2020 Mar 16; 12(3).
    View PubMed
  72. Recio-Boiles A, Vondrak J, Veeravelli S, Mancuso JJ, Saboda K, Roe DJ, Riaz IB, Scott AJ, Elquza E, McBride A, Babiker HM. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. Ann Pancreat Cancer. 2020 Mar; 3 Epub 2020 Mar 09
    View PubMed
  73. Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020 Mar; 85(3):621-626. Epub 2020 Feb 08.
    View PubMed
  74. Alhifany AA, McBride A, Almutairi AR, Cheema E, Shahbar A, Alatawi Y, Alharbi AS, Babiker H, MacDonald K, Aapro M, Abraham I. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. Support Care Cancer. 2020 Mar; 28(3):1031-1039. Epub 2019 Dec 10.
    View PubMed
  75. Recio-Boiles A, Hammad H, Howell K, Kalb BT, Nfonsam VN, Scott AJ, Babiker HM, Elquza E. Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review. J Gastrointest Cancer. 2020 Mar; 51(1):254-259.
    View PubMed
  76. Alkhushaym N, Almutairi AR, Althagafi A, Fallatah SB, Oh M, Martin JR, Babiker HM, McBride A, Abraham I. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert Opin Drug Saf. 2020 Mar; 19(3):327-334. Epub 2020 Jan 21.
    View PubMed
  77. Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol. 2020 Jan 1; 6 (1):125-132
    View PubMed
  78. Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, Patel H, Elquza E, McBride A. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol. 2019 Oct 15; 11(10):866-876.
    View PubMed
  79. Almutairi AR, Alkhatib N, Martin J, Babiker HM, Garland LL, McBride A, Abraham I. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:16-25. Epub 2019 Jul 10.
    View PubMed
  80. Chong BW, Bendok BR, Krishna C, Sattur M, Brown BL, Tawk RG, Miller DA, Rangel-Castilla L, Babiker H, Frakes DH, Theiler A, Cloft H, Kallmes D, Lanzino G. A Multicenter Pilot Study on the Clinical Utility of Computational Modeling for Flow-Diverter Treatment Planning. AJNR Am J Neuroradiol. 2019 Oct; 40 (10):1759-1765 Epub 2019 Sept 26
    View PubMed
  81. Davis LE, Nicholls LA, Babiker HM, Liau J, Mahadevan D. PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. Cancer Immunol Res. 2019 Sep; 7(9):1396-1400. Epub 2019 Aug 05.
    View PubMed
  82. Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs. 2019 Aug; 37 (4):636-645 Epub 2018 Sept 28
    View PubMed
  83. Babiker HM, Davis L, Larson K, Placencia C, Swensen C, Tenneti P, Lim M, Cañamar R, Curtis J, Castillo E, Mancuso J, Rensvold D, Martinez S, Macias L, Recio-Boiles A, Chandana SR, Mahadevan D. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations. Expert Opin Investig Drugs. 2019 Aug; 28(8):675-686. Epub 2019 Jul 29.
    View PubMed
  84. Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019 Jul; 28(7):583-592. Epub 2019 Jun 21.
    View PubMed
  85. Recio-Boiles A, Nallagangula A, Veeravelli S, Vondrak J, Saboda K, Roe D, Elquza E, McBride A, Babiker HM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2019 Jun; 2. Epub 2019 Jun 11.
    View PubMed
  86. Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019 Jun; 79(8):880-895. Epub 2019 Mar 22.
    View PubMed
  87. Algotar A, Hsu CH, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, Abraham I, Kumar R, Ligibel J, Courneya KS, Thomson C. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. JMIR Res Protoc. 2019 Feb 05; 8(2):e12579.
    View PubMed
  88. Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019 Feb; 28(2):161-177. Epub 2018 Dec 16.
    View PubMed
  89. Babiker HM, Riaz IB, Husnain M, Borad MJ. Erratum: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]. Oncolytic Virother. 2019; 8:1. Epub 2019 Jan 04.
    View PubMed
  90. Almutairi AR, Alkhatib NS, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer LD, McBride A, Abraham I. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatol. 2019 Jan 01; 155(1):22-28.
    View PubMed
  91. Bailey M, Maestas T, Betancourt R, Mikhael D, Babiker HM. A Rare Cause of Thrombotic Thrombocytopenia Purpura- (TTP-) Like Syndrome, Vitamin B12 Deficiency: Interpretation of Significant Pathological Findings. Case Rep Hematol. 2019; 2019:1529306. Epub 2019 Mar 18.
    View PubMed
  92. Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs Real World Outcomes. 2018 Sep; 5(3):149-159.
    View PubMed
  93. Tenneti P, Borad MJ, Babiker HM. Exploring the role of oncolytic viruses in hepatobiliary cancers. Immunotherapy. 2018 Aug; 10(11):971-986. Epub 2018 Jun 14.
    View PubMed
  94. Aguiar P Jr, Giglio AD, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, Lopes G Jr, De Mello RA. Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. Immunotherapy. 2018 Aug; 10 (10):887-897
    View PubMed
  95. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26; 379(4):341-351. Epub 2018 Jun 04.
    View PubMed
  96. Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, Cassagnol M, Camenisch TD, Anwer F, Hollands JM. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018 Jun; 126:186-200. Epub 2018 Mar 29.
    View PubMed
  97. Aguiar PN Jr, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2018 Apr 1; 29 (4):1078
    View PubMed
  98. Babiker HM, Glode AE, Cooke LS, Mahadevan D. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018 Apr; 27(4):407-412. Epub 2018 Apr 03.
    View PubMed
  99. Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018 Jan 15; 24(2):266-275. Epub 2017 Aug 01.
    View PubMed
  100. Larson K, Babiker HM, Kovoor A, Liau J, Eldersveld J, Elquza E. Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma. Case Rep Oncol Med. 2018; 2018:7127048. Epub 2018 Mar 01.
    View PubMed
  101. Aguiar PN Jr, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017 Sep 1; 28 (9):2256-2263
    View PubMed
  102. Babiker HM, McBride A, Cooke LS, Mahadevan D. Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors. Expert Opin Investig Drugs. 2017 Sep; 26(9):1063-1072. Epub 2017 Jul 30.
    View PubMed
  103. Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anticancer Drugs. 2017 Feb; 28 (2):127-132
    View PubMed
  104. Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother. 2017; 6:11-18. Epub 2017 Feb 09.
    View PubMed
  105. Aguiar PN Jr, De Mello R, Tadokoro H, Babiker HM, Lopes G.. Cost effectiveness and estimate of economic impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. Annals of Oncology. 2016; 27(Issue suppl_6, 1 October 2016):1224P.
  106. Nair P, Chong BW, Indahlastari A, Lindsay J, DeJeu D, Parthasarathy V, Ryan J, Babiker H, Workman C, Gonzalez LF, Frakes D. Hemodynamic characterization of geometric cerebral aneurysm templates. J Biomech. 2016 Jul 26; 49 (11):2118-2126 Epub 2015 Nov 28
    View PubMed
  107. Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H, Malangone SA, Borad MJ, Dragovich T. Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. Cancer Invest. 2016; 34 (2):57-63 Epub 2016 Jan 25
    View PubMed
  108. Babiker HM, Green MR, Nelson MA, Elquza E. Oxaliplatin-induced neuropathy: a tale of two electrolytes. Support Care Cancer. 2015 Jun; 23(6):1483-5. Epub 2015 Mar 24.
    View PubMed
  109. Borad MJ, Babiker HM, Anthony S, Mita M, Buchbinder A, Keilani T, Grem J. A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma. Cancer Invest. 2015 May; 33 (5):172-9 Epub 2015 Apr 06
    View PubMed
  110. Ong SY, Taverna J, Jokerst C, Enzler T, Hammode E, Rogowitz E, Green MR, Babiker HM. Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix. Case Rep Oncol Med. 2015; 2015:212543. Epub 2015 Nov 03.
    View PubMed
  111. Babiker HM, Proytcheva M. Basophilic blast phase of chronic myelogenous leukemia. Blood. 2014 Oct 09; 124(15):2464.
    View PubMed
  112. Rogowitz E, Babiker HM, Kanaan M, Millius RA, Ringenberg QS, Bishop M. Neuroblastoma of the elderly, an oncologist's nightmare: case presentation, literature review and SEER database analysis. Exp Hematol Oncol. 2014; 3:20. Epub 2014 Jul 17.
    View PubMed
  113. Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R. "Almost bleeding to death": the conundrum of acquired amegakaryocytic thrombocytopenia. Case Rep Hematol. 2014; 2014:806541. Epub 2014 Feb 06.
    View PubMed
  114. Taverna JA, Babiker HM, Yun S, Bishop MC, Lau-Braunhut S, Meyer PN, Enzler T. The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res. 2014; 2(1):23. Epub 2014 Dec 05.
    View PubMed
  115. Babiker HM, Wiedenbeck T, Robetorye RS, Acharya U, Wilansky S, Kusne S. Acute systemic viral infection masquerading as an infiltrating lymphoma in an elderly patient: a case report and review of the literature. Case Rep Med. 2013; 2013:318358 Epub 2013 Feb 12
    View PubMed
  116. Rogowitz E, Babiker HM, Krishnadasan R, Jokerst C, Miller TP, Bookman M. Heart of lymphoma: primary mediastinal large B-cell lymphoma with endomyocardial involvement. Case Rep Oncol Med. 2013; 2013:814291. Epub 2013 Oct 01.
    View PubMed
  117. Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer. 2012; 3:345-53 Epub 2012 Aug 17
    View PubMed
  118. Babiker H, Stiefeld R, Vikram HR. Granulomatous Cholangitis as a complication of intravesical BCG administration for bladder cancer. British Journal of Urology International. 2011.
  119. Change Chang J, Babiker H, Serynek S. Compliance with the Joint National Committee VII guidelines and effectiveness in the management of hypertension in an outpatient community care clinic at a teaching institution. Resident Research Journal. 2007.